Globus Medical, Inc. with ticker code (GMED) have now 13 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $100.00 and $55.00 suggesting an average Analsyt target price of $79.31. Given that the stocks previous close was at $70.35 this is indicating there is a potential upside of 12.7%. The 50 day moving average now sits at $70.75 and the 200 moving average now moves to $60.70. The market cap for the company is 9.55B. The price for the stock stands currently at: $70.52 USD
The potential market cap would be $10,765,079,860 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 352.6, revenue per share of $17.13 and a 6.11% return on assets.
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions. The Company’s product categories include Musculoskeletal Solutions and Enabling Technologies. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the majority of conditions affecting the spine, including degenerative conditions, deformity, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery (MIS) techniques. It includes traditional fusion implants, such as pedicle screws and rod systems. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip. Enabling Technologies is comprised of imaging, navigation and robotics (INR) solutions for assisted surgery.
